MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE

Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases

Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455

The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease

Pickrell, A. M., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.007 · Cited by 2,310

Mitochondrial Complex I Deficiency in Parkinson's Disease

Schapira, A. H. V., Cooper, J. M., Dexter, D., Clark, J. B., Jenner, P., & Marsden, C. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb02325.x · Cited by 2,283

Mitophagy and Quality Control Mechanisms in Mitochondrial Maintenance

Pickles, S., Vigié, P., & Youle, R. J. (2018) · Current Biology · doi:10.1016/j.cub.2018.01.004 · Cited by 2,081

The Role of Oxidative Stress in Parkinson's Disease

Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845

Parkinson disease

Balestrino, R., & Schapira, A. H. V. (2020) · European Journal of Neurology · doi:10.1111/ene.14108 · Cited by 1,508

Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling.

Lee, J., Giordano, S., & Zhang, J. (2012) · Biochemical Journal · doi:10.1042/bj20111451 · Cited by 1,438

Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants

Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.

Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E. R., & Mizuno, Y. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2696 · Cited by 981

Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy

Gegg, M. E., Cooper, J. M., Chau, K.-Y., Rojo, M., Schapira, A. H. V., & Taanman, J.-W. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq419 · Cited by 910

Mitochondria in the aetiology and pathogenesis of Parkinson's disease

Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883

Oxidative stress and Parkinson’s disease

Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., & Jackson-Lewis, V. R. (2015) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2015.00091 · Cited by 878

Expanding insights of mitochondrial dysfunction in Parkinson's disease

Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869

The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration

Mahul-Mellier, A.-L., Burtscher, J., Maharjan, N., Weerens, L., Croisier, M., Kuttler, F., Leleu, M., Knott, G. W., & Lashuel, H. A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913904117 · Cited by 710

The Role of Excitotoxicity in Neurodegenerative Disease

Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723

Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress

Gautier, C. A., Kitada, T., & Shen, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802076105 · Cited by 698

Mitochondrial dysfunction in Parkinson's disease

Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688

PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1

Pridgeon, J. W., Olzmann, J. A., Chin, L.-S., & Li, L. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050172 · Cited by 596

Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease

Ryan, B. J., Hoek, S., Fon, E. A., & Wade-Martins, R. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.02.003 · Cited by 524

PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease

Ge, P., Dawson, V. L., & Dawson, T. M. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00367-7 · Cited by 496

A Guide to Neurotoxic Animal Models of Parkinson's Disease

Tieu, K. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009316 · Cited by 483

Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases

Jellinger, K., Paulus, W., Grundke-Iqbal, I., Riederer, P., & Youdim, M. B. H. (1990) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02252926 · Cited by 445

Production of Reactive Oxygen Species in Brain Mitochondria: Contribution by Electron Transport Chain and Non–Electron Transport Chain Sources

Adam-Vizi, V. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1140 · Cited by 439

Mitochondrial respiratory complex I: Structure, function and implication in human diseases

Sharma, L., Lu, J., & Bai, Y. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787846578 · Cited by 438

Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress

Tretter, L., & Adam-Vizi, V. (2005) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2005.1764 · Cited by 434

Low platelet mitochondrial complex I and complex II/III activity in early untreated parkinson's disease

Haas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435

The three ‘P’s of mitophagy: PARKIN.; PINK1.; and post-translational modifications

Durcan, T. M., & Fon, E. A. (2015) · Genes & Development · doi:10.1101/gad.262758.115 · Cited by 400

Mitochondrial dysfunction in neurodegenerative disorders

Klemmensen, M. M., Borrowman, S. H., Pearce, C., Pyles, B., & Chandra, B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.002 · Cited by 396

An introduction to the free radical hypothesis in Parkinson's disease

Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382

The Role of Mitochondria in Neurodegenerative Diseases: the Lesson from Alzheimer’s Disease and Parkinson’s Disease

Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378

Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis

Calabrese, V., Santoro, A., Monti, D., Crupi, R., Di Paola, R., Latteri, S., Cuzzocrea, S., Zappia, M., Giordano, J., Calabrese, E. J., et al. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.10.379 · Cited by 356

The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson's disease

Schöndorf, D. C., Ivanyuk, D., Baden, P., Sanchez-Martinez, A., De Cicco, S., Yu, C., Giunta, I., Schwarz, L. K., Di Napoli, G., Panagiotakopoulou, V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.009 · Cited by 337

Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress

Pickrell, A. M., Huang, C.-H., Kennedy, S. R., Ordureau, A., Sideris, D. P., Hoekstra, J. G., Harper, J. W., & Youle, R. J. (2015) · Neuron · doi:10.1016/j.neuron.2015.06.034 · Cited by 327

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease

Brakedal, B., Dölle, C., Riemer, F., Ma, Y., Nido, G. S., Skeie, G. O., Craven, A. R., Schwarzlmüller, T., Brekke, N., Diab, J., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.001 · Cited by 323

Oxidative and nitrosative stress in Parkinson's disease

Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300

NRF2 as a Therapeutic Target in Neurodegenerative Diseases

Brandes, M. S., & Gray, N. E. (2020) · ASN Neuro · doi:10.1177/1759091419899782 · Cited by 297

Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases

Cai, R., Zhang, Y., Simmering, J. E., Schultz, J. L., Li, Y., Fernandez-Carasa, I., Consiglio, A., Raya, A., Polgreen, P. M., Narayanan, N. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129987 · Cited by 286

Nitric oxide inhibits mitochondrial NADH:ubiquinone reductase activity through peroxynitrite formation

RIOBÓ, N. A., CLEMENTI, E., MELANI, M., BOVERIS, A., CADENAS, E., MONCADA, S., & PODEROSO, J. J. (2001) · Biochemical Journal · doi:10.1042/bj3590139 · Cited by 278

The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders

Morris, G., & Berk, M. (2015) · BMC Medicine · doi:10.1186/s12916-015-0310-y · Cited by 245

Brain region‐specific deficit in mitochondrial electron transport chain complexes in children with autism

Chauhan, A., Gu, F., Essa, M. M., Wegiel, J., Kaur, K., Brown, W. T., & Chauhan, V. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07189.x · Cited by 243

PINK1, Parkin, and Mitochondrial Quality Control: What can we Learn about Parkinson’s Disease Pathobiology?

Truban, D., Hou, X., Caulfield, T. R., Fiesel, F. C., & Springer, W. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160989 · Cited by 237

Levodopa in the treatment of Parkinson's disease

Schapira, A. H. V., Emre, M., Jenner, P., & Poewe, W. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02697.x · Cited by 231

Mitochondrial Medicine for Aging and Neurodegenerative Diseases

Reddy, P. H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8044-z · Cited by 230

The Role of Iron in Neurodegeneration: Prospects for Pharmacotherapy of Parkinson??s Disease

Jellinger, K. A. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00004 · Cited by 218

Effect of Creatine Monohydrate on Clinical Progression in Patients With Parkinson Disease: A Randomized Clinical Trial

Kieburtz, K., Tilley, B. C., Elm, J. J., Babcock, D., Hauser, R., Ross, G. W., Augustine, A. H., Augustine, E. U., Aminoff, M. J., Bodis-Wollner, I. G., et al. (2015) · JAMA · doi:10.1001/jama.2015.120 · Cited by 207

Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance

Heeman, B., Van den Haute, C., Aelvoet, S.-A., Valsecchi, F., Rodenburg, R. J., Reumers, V., Debyser, Z., Callewaert, G., Koopman, W. J. H., Willems, P. H. G. M., et al. (2011) · Journal of Cell Science · doi:10.1242/jcs.078303 · Cited by 198

Sources and implications of NADH/NAD+ redox imbalance in diabetes and its complications

Yan, L.-J., Wu, J., Jin, Z., & Zheng, H. (2016) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s106087 · Cited by 198

Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells

Gegg, M. E., Cooper, J. M., Schapira, A. H. V., & Taanman, J.-W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004756 · Cited by 198

Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms

Váradi, C. (2020) · Biology · doi:10.3390/biology9050103 · Cited by 196

Altered Mitochondrial DNA Methylation Pattern in Alzheimer Disease–Related Pathology and in Parkinson Disease

Blanch, M., Mosquera, J. L., Ansoleaga, B., Ferrer, I., & Barrachina, M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.004 · Cited by 192

A Perspective on Nrf2 Signaling Pathway for Neuroinflammation: A Potential Therapeutic Target in Alzheimer's and Parkinson's Diseases

Saha, S., Buttari, B., Profumo, E., Tucci, P., & Saso, L. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.787258 · Cited by 185

Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model

Choi, W.-S., Palmiter, R. D., & Xia, Z. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009132 · Cited by 183

Lewy Body Pathology in Alzheimer's Disease

Kotzbauer, P. T., Tojanowski, J. Q., & Lee, V. M. V. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:225 · Cited by 177

Mitochondrial dysfunction in Parkinson's disease

Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175

miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1)

Kim, J., Fiesel, F. C., Belmonte, K. C., Hudec, R., Wang, W.-X., Kim, C., Nelson, P. T., Springer, W., & Kim, J. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0121-4 · Cited by 163

Novel tactics for neuroprotection in Parkinson's disease: role of antibiotics, polyphenols and neuropeptides

Reglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162

Interaction of Mitochondrial Calcium and ROS in Neurodegeneration

Baev, A. Y., Vinokurov, A. Y., Novikova, I. N., Dremin, V. V., Potapova, E. V., & Abramov, A. Y. (2022) · Cells · doi:10.3390/cells11040706 · Cited by 162

Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease

Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159

PINK1 function in health and disease

Deas, E., Plun‐Favreau, H., & Wood, N. W. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900024 · Cited by 154

Diet in Parkinson’s Disease: Critical Role for the Microbiome

Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145

Redox status of plasma coenzyme Q10 indicates elevated systemic oxidative stress in Parkinson's disease

Sohmiya, M., Tanaka, M., Wei Tak, N., Yanagisawa, M., Tanino, Y., Suzuki, Y., Okamoto, K., & Yamamoto, Y. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.05.007 · Cited by 143

Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder

Nishiwaki, H., Hamaguchi, T., Ito, M., Ishida, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · mSystems · doi:10.1128/msystems.00797-20 · Cited by 133

Striatal Neuroinflammation Promotes Parkinsonism in Rats

Choi, D.-Y., Liu, M., Hunter, R. L., Cass, W. A., Pandya, J. D., Sullivan, P. G., Shin, E.-J., Kim, H.-C., Gash, D. M., & Bing, G. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005482 · Cited by 141

Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: An update on current advances and impediments

Rehman, M. U., Sehar, N., Dar, N. J., Khan, A., Arafah, A., Rashid, S., Rashid, S. M., & Ganaie, M. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104961 · Cited by 130

Ursodeoxycholic acid ameliorates apoptotic cascade in the rotenone model of Parkinson's disease: Modulation of mitochondrial perturbations

Abdelkader, N. F., Safar, M. M., & Salem, H. A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9043-8 · Cited by 127

Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson’s disease

Simon, D. K., Lin, M. T., Zheng, L., Liu, G.-J., Ahn, C. H., Kim, L. M., Mauck, W. M., Twu, F., Beal, M. F., & Johns, D. R. (2004) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00037-x · Cited by 118

Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease

Milanese, C., Cerri, S., Ulusoy, A., Gornati, S. V., Plat, A., Gabriels, S., Blandini, F., Di Monte, D. A., Hoeijmakers, J. H., & Mastroberardino, P. G. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0848-7 · Cited by 118

Pathogenic Mechanisms of Neurodegeneration in Parkinson Disease

Mullin, S., & Schapira, A. H. V. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2014.09.010 · Cited by 108

Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: A paradigm for multifactorial neurodegenerative diseases?

Galea, E., Launay, N., Portero-Otin, M., Ruiz, M., Pamplona, R., Aubourg, P., Ferrer, I., & Pujol, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.005 · Cited by 108

Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration

Wilkins, H. M., Weidling, I. W., Ji, Y., & Swerdlow, R. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00508 · Cited by 102

Coenzyme Q10 Depletion in Medical and Neuropsychiatric Disorders: Potential Repercussions and Therapeutic Implications

Morris, G., Anderson, G., Berk, M., & Maes, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8477-8 · Cited by 96

A Novel Polymerase γ Mutation in a Family With Ophthalmoplegia, Neuropathy, and Parkinsonism

Mancuso, M., Filosto, M., Oh, S. J., & DiMauro, S. (2004) · Archives of Neurology · doi:10.1001/archneur.61.11.1777 · Cited by 92

Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers

Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92

Uptake and mitochondrial dysfunction of alpha-synuclein in human astrocytes, cortical neurons and fibroblasts

Braidy, N., Gai, W.-P., Xu, Y. H., Sachdev, P., Guillemin, G. J., Jiang, X.-M., Ballard, J. W. O., Horan, M. P., Fang, Z. M., Chong, B. H., et al. (2013) · Translational Neurodegeneration · doi:10.1186/2047-9158-2-20 · Cited by 91

Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery

Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88

Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes

Mosconi, L., Berti, V., Swerdlow, R. H., Pupi, A., Duara, R., & de Leon, M. (2010) · Human Genomics · doi:10.1186/1479-7364-4-3-170 · Cited by 85

Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease

Simmering, J. E., Welsh, M. J., Liu, L., Narayanan, N. S., & Pottegård, A. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.5157 · Cited by 84

The Oxygen Paradox, the French Paradox, and age-related diseases

Davies, J. M. S., Cillard, J., Friguet, B., Cadenas, E., Cadet, J., Cayce, R., Fishmann, A., Liao, D., Bulteau, A.-L., Derbré, F., et al. (2017) · GeroScience · doi:10.1007/s11357-017-0002-y · Cited by 82

Calcium, Bioenergetics, and Parkinson’s Disease

Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79

Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson’s Disease and Dopa-Responsive Dystonia

Kawahata, I., & Fukunaga, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113779 · Cited by 71

Deficiency of Parkinson’s disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation

Delgado-Camprubi, M., Esteras, N., Soutar, M. P., Plun-Favreau, H., & Abramov, A. Y. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2016.104 · Cited by 71

Vulnerability of mesostriatal dopaminergic neurons in Parkinson’s disease

González-Hernández, T. (2010) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2010.00140 · Cited by 65

Mitochondrial Dynamics and Parkinson's Disease: Focus on Parkin

Lim, K.-L., Ng, X.-H., Grace, L. G.-Y., & Yao, T.-P. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4105 · Cited by 64

Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson?s disease

Winkler-Stuck, K., Kirches, E., Mawrin, C., Dietzmann, K., Lins, H., Wallesch, C.-W., Kunz, W. S., & Wiedemann, F. R. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0195-y · Cited by 63

Extensive respiratory chain defects in inhibitory interneurones in patients with mitochondrial disease

Lax, N. Z., Grady, J., Laude, A., Chan, F., Hepplewhite, P. D., Gorman, G., Whittaker, R. G., Ng, Y., Cunningham, M. O., & Turnbull, D. M. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12238 · Cited by 61

Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson’s Disease Patients

Yakhine-Diop, S. M. S., Niso-Santano, M., Rodríguez-Arribas, M., Gómez-Sánchez, R., Martínez-Chacón, G., Uribe-Carretero, E., Navarro-García, J. A., Ruiz-Hurtado, G., Aiastui, A., Cooper, J. M., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1206-6 · Cited by 57

Exercise does not protect against MPTP-induced neurotoxicity in BDNF happloinsufficent mice

Gerecke, K. M., Jiao, Y., Pagala, V., & Smeyne, R. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043250 · Cited by 53

Idebenone Has Distinct Effects on Mitochondrial Respiration in Cortical Astrocytes Compared to Cortical Neurons Due to Differential NQO1 Activity

Jaber, S. M., Ge, S. X., Milstein, J. L., VanRyzin, J. W., Waddell, J., & Polster, B. M. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1632-17.2020 · Cited by 48

Abnormal carbohydrate metabolism in cerebrospinal fluid in Rett syndrome

Matsuishi, T., Urabe, F., Percy, A. K., Komori, H., Yamashita, Y., Schultz, R. S., Ohtani, Y., Kuriya, N., & Kato, H. (1994) · Journal of Child Neurology · doi:10.1177/088307389400900105 · Cited by 41

Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease

Chen, C., Mossman, E., Malko, P., McDonald, D., Blain, A. P., Bone, L., Erskine, D., Filby, A., Vincent, A. E., Hudson, G., et al. (2022) · Movement Disorders · doi:10.1002/mds.28849 · Cited by 36

Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases

H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35

Aspects of innate immunity and Parkinson's disease

Huang, Y., & Halliday, G. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00033 · Cited by 22

Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson’s disease

Patki, G. (2009) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.003.2009 · Cited by 20

Mitochondrial Function and Neurodegenerative Diseases

Wilkins, H. M., Weidling, I., Koppel, S., Wang, X., von Schulze, A., & Swerdlow, R. H. (2018) · The Molecular and Cellular Basis of Neurodegenerative Diseases · doi:10.1016/b978-0-12-811304-2.00013-4 · Cited by 2